Loading stock…

Guardant Health, Inc. (GH) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Guardant Health, Inc.

GHMarket cap $23BPrice $168.3

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Develops blood tests that detect cancer through simple DNA screening, skipping invasive biopsies entirely. Its Shield test is the first FDA-approved blood-based colorectal cancer screening tool, reshaping how doctors catch tumors before symptoms even appear.

In Bastion Portfolios?

52W Return+157%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+30%10

Revenue Forecast

Rev CAGR (1y)+38%9

Rev CAGR (3y)+36%10

Rev CAGR (5y)+34%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-40%1

Net Income Margin-38%1

Free Cash Flow Margin-20%2

Debt

Net Debt/EBITDAna–

Efficiency

ROEna–

ROA-28%1

Earnings Stabilityna–

GEAR+WEAK15

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)1381

P/BVna–

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-1.1%2

Dividend Yieldna–

Momentum

Short term

1 month return+5%9

3 month return+8%8

YTD return+65%10

Mid term

Price vs 52wHigh88%8

1 year return+158%10

Long term

3 year return+491%10

5 year return+61%6

Risk Shield

Price Risk

Beta1.32

Volatility57%2

Free Cash Flow

Free Cash Flow Margin-20%2

Free Cash Flow Yield-1.1%2

Quality

ROCE-35%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

GHGuardant Health

Revenue FY25$982M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y+38%9

Revenue, next 3Y, CAGR+36%10

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 36%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 30%/yr over the last 3 years and is set to grow 36%/yr from here.

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG93 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+8%8

YTD return+65%10

MID & LONG-TERM▾SCORE

% of 52-week high88%8

1-year return+158%10

3-year return+491%10

5-year return+61%6

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +491% over three years and +61% over five, ahead of 70% of the market.

It's up 158% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+8%) and so far this year (+65%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Guardant. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GHGuardant Health

Revenue FY25$982M

GROWTH RATING↗

VERY STRONG89 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+30%10

Revenue, next 1Y+38%9

Revenue, next 3Y, CAGR+36%10

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 89% of companies worldwide.

Revenue grew 30%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 36%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 30%/yr over the last 3 years and is set to grow 36%/yr from here.

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG93 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+5%9

3-month return+8%8

YTD return+65%10

MID & LONG-TERM▾SCORE

% of 52-week high88%8

1-year return+158%10

3-year return+491%10

5-year return+61%6

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +491% over three years and +61% over five, ahead of 70% of the market.

It's up 158% over the past year, but 12% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+5%), over three months (+8%) and so far this year (+65%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Guardant. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community